Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $1.2 million.

  • Entrada Therapeutics' Depreciation & Amortization (CF) rose 33.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 22.36%. This contributed to the annual value of $3.8 million for FY2024, which is 33.76% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Depreciation & Amortization (CF) of $1.2 million as of Q3 2025, which was up 9.09% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q3 2025 and a low of $400,000 during Q1 2022.
  • Over the past 3 years, Entrada Therapeutics' median Depreciation & Amortization (CF) value was $900,000 (recorded in 2024), while the average stood at $887,000.
  • Data for Entrada Therapeutics' Depreciation & Amortization (CF) shows a peak YoY surged of 72.64% (in 2024) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $500,000 in 2022, then spiked by 47.20% to $736,000 in 2023, then skyrocketed by 35.87% to $1.0 million in 2024, then soared by 33.33% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.1 million for Q2 2025, and $946,000 during Q1 2025.